EUVIMEDEUVIMED entdecken
Crossref

Dynamics of measurable residual disease for risk stratification and guiding allogeneic transplant in acute myeloid leukaemia patients with myelodysplasia‐related mutations in first remission

Ling Jiang iD, Jiaying Cheng, Junya Sun, Yujiao Zhang, Quan Wu, Yun Huang, Zhiquan Long, Ping Yan, Xuejie Jiang iD

British Journal of Haematology · 2025

DOI: 10.1111/bjh.19917 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Ling Jiang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Clinical Decision-Making, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Accurate classification and risk prediction are critical for therapeutic decision‐making in patients with acute myeloid leukaemia (AML). Myelodysplasia‐related (MR) gene mutations are classified as adverse genetic factors by the European LeukaemiaNet‐2022 guidelines. However, their prognostic value in de novo AML remains controversial. This study retrospectively analysed 188 patients with de novo AML‐MR, stratifying them into four subgroups based on dynamic measurable residual disease (MRD) after induction, one or two courses of consolidation chemotherapy. The median follow‐up was 36.8 months (4.6–73.7). Patients with persistent or recurrent MRD positivity after the second consolidation had the poorest 3‐year relapse‐free survival (RFS), overall survival (OS) and cumulative incidence of relapse compared to the other groups ( p < 0.001). Multivariable analysis identified this high‐risk group as an independent risk factor for both RFS and OS. We observed significant heterogeneity of OS benefit from allogeneic stem cell transplantation (allo‐SCT) by MRD‐risk groups, with substantial OS advantage for patients in subgroup D (3‐year OS: allo‐SCT 70.0% vs. 18.2% without, p < 0.001) but no benefit for others ( p = 0.047 for interaction). This study underscores the importance of dynamic MRD in refining risk stratification and identifying de novo AML patients with MR mutations who would benefit from allo‐SCT during the first complete remission.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteClinical Decision-MakingHematopoietic Stem Cell TransplantationNeoplasm, ResidualRisk AssessmentTransplantation, HomologousMutationConsolidation ChemotherapyPrognosisFollow-Up StudiesTreatment OutcomeRetrospective StudiesHumansMaleFemaleAdolescentYoung AdultAdultMiddle AgedAgedAntineoplastic Combined Chemotherapy ProtocolsProgression-Free Survival

Stichwörter der Autor:innen

acute myeloid leukaemiameasurable residual diseasemyelodysplasia‐related mutationsrisk stratificationstem cell transplantation

Autor:innen und Institutionen

  • Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Department of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

ORCID-Profile: Ling Jiang, Xuejie Jiang

Förderung

  • Basic and Applied Basic Research Foundation of Guangdong Province
  • National Natural Science Foundation of China

Zitieren

APA

Jiang, L., Cheng, J., Sun, J., Zhang, Y., Wu, Q., Huang, Y., Long, Z., Yan, P., & Jiang, X. (2025). Dynamics of measurable residual disease for risk stratification and guiding allogeneic transplant in acute myeloid leukaemia patients with myelodysplasia‐related mutations in first remission. British Journal of Haematology. https://doi.org/10.1111/bjh.19917

Vancouver

Jiang L, Cheng J, Sun J, Zhang Y, Wu Q, Huang Y, et al. Dynamics of measurable residual disease for risk stratification and guiding allogeneic transplant in acute myeloid leukaemia patients with myelodysplasia‐related mutations in first remission. British Journal of Haematology. 2025. doi:10.1111/bjh.19917

BibTeX
@article{Jiang2025,
  author = {Jiang, Ling and Cheng, Jiaying and Sun, Junya and Zhang, Yujiao and Wu, Quan and Huang, Yun and Long, Zhiquan and Yan, Ping and Jiang, Xuejie},
  title = {Dynamics of measurable residual disease for risk stratification and guiding allogeneic transplant in acute myeloid leukaemia patients with myelodysplasia‐related mutations in first remission},
  journal = {British Journal of Haematology},
  year = {2025},
  doi = {10.1111/bjh.19917}
}
Kostenlos starten →